Lyra therapeutics presents new positive phase 2 lantern 6-month follow-up and lyr-210 pharmacokinetic data, and lantern manuscript wins award at the 67th annual meeting of the american rhinologic society

Watertown, mass., oct. 4, 2021 /prnewswire/ -- lyra therapeutics, inc. (nasdaq: lyra), a clinical-stage therapeutics company leveraging its proprietary xtreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ent) passages and other diseased tissues, announced that new, positive lyr-210 data from the lantern 6-month post-treatment evaluation and recently completed pharmacokinetic study, were the subject of two oral presentations at the 67th annual meeting of the american rhinologic society (ars) on october 1-2.
LYRA Ratings Summary
LYRA Quant Ranking